Review
Rarely metastasizing soft tissue tumours
Correction(s) for this article
-
Erratum
- Volume 64Issue 4Histopathology
- pages: 608-608
- First Published online: February 4, 2014
D Chas Mangham,
Lars-Gunnar Kindblom,
D Chas Mangham
Department of Musculoskeletal Pathology, Royal Orthopaedic Hospital NHS Trust, Robert Aitken Institute of Clinical Research and School of Cancer Sciences, Medical School, Birmingham University, Birmingham, UK
Department of Musculoskeletal Pathology, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust, Oswestry, UK
Search for more papers by this authorCorresponding Author
Lars-Gunnar Kindblom
Department of Musculoskeletal Pathology, Royal Orthopaedic Hospital NHS Trust, Robert Aitken Institute of Clinical Research and School of Cancer Sciences, Medical School, Birmingham University, Birmingham, UK
Address for correspondence: L-G Kindblom, Department of Musculoskeletal Pathology, Royal Orthopaedic Hospital NHS Trust, Robert Aitken Institute of Clinical Research, Birmingham B15 2TT, UK. e-mail: [email protected]Search for more papers by this authorD Chas Mangham,
Lars-Gunnar Kindblom,
D Chas Mangham
Department of Musculoskeletal Pathology, Royal Orthopaedic Hospital NHS Trust, Robert Aitken Institute of Clinical Research and School of Cancer Sciences, Medical School, Birmingham University, Birmingham, UK
Department of Musculoskeletal Pathology, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust, Oswestry, UK
Search for more papers by this authorCorresponding Author
Lars-Gunnar Kindblom
Department of Musculoskeletal Pathology, Royal Orthopaedic Hospital NHS Trust, Robert Aitken Institute of Clinical Research and School of Cancer Sciences, Medical School, Birmingham University, Birmingham, UK
Address for correspondence: L-G Kindblom, Department of Musculoskeletal Pathology, Royal Orthopaedic Hospital NHS Trust, Robert Aitken Institute of Clinical Research, Birmingham B15 2TT, UK. e-mail: [email protected]Search for more papers by this authorThe copyright line for this paper has been changed since first published
on 28 November 2013, due to removal of Open Access.
Abstract
Soft tissue tumours that rarely metastasize have been afforded their own subcategory in recent WHO classifications. This review discusses the nature of these tumours and the difficulty in constructing usefully simple classifications for heterogeneous and complex groups of tumours. We also highlight the specific rarely metastasizing soft tissue tumours that have been recently added to the WHO classification (phosphaturic mesenchymal tumour, pseudomyogenic haemangioendothelioma) and those entities where there have been recent important defining genetic discoveries (myxoinflammatory fibroblastic sarcoma, solitary fibrous tumour, myoepitheliomas).
References
- 1 CDM Fletcher, KK Unni, F Mertens eds. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press, 2002.
- 2 CDM Fletcher, JA Bridge, CW Pancras, FM Hogendoorn eds. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press, 2013.
- 3Doyle LA, Fletcher CD. Metastasizing ‘benign’ cutaneous fibrous histiocytoma: a clinicopathologic study of 16 cases. Am. J. Surg. Pathol. 2013; 37; 484–495.
- 4Calonje E, Mentzel T, Fletcher CD. Cellular benign fibrous histiocytoma. Clinicopathologic analysis of 74 cases of a distinctive variant of cutaneous fibrous histiocytoma with frequent recurrence. Am. J. Surg. Pathol. 1994; 18; 668–676.
- 5Lodewick E, Avermaete A, Blom WA et al. Fetal case of cellular fibrous histiocytoma: case report and review of literature. Am. J. Dermatopathol.. 2013. [Epub ahead of print].
10.1097/DAD.0b013e318299f28c Google Scholar
- 6Somerhausen NS, Fletcher CD. Diffuse-type giant cell tumor: clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease. Am. J. Surg. Pathol. 2000; 24; 479–492.
- 7Antonescu CR, Stratakis CA, Woodruff JM. Melanotic schwannoma. In CDM Fletcher, JS Bridge, CW Pancras, FM Hogendoorn eds. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press, 2013; 173.
- 8Miettinen MM, Corless CL, Debiec-Rychter M et al. Gastrointestinal stromal tumours. In CDM Fletcher, JS Bridge, CW Pancras, FM Hogendoorn eds. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press, 2013; 164–167.
- 9Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors: a polymorphous group causing osteomalacia or rickets. Cancer 1987; 15; 1442–1454.
- 10Weidner N. Review and update: oncogenic osteomalacia-rickets. Ultrastruct. Pathol. 1991; 15; 317–333.
- 11Folpe AL, Fanburg-Smith JC, Billings SD et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am. J. Surg. Pathol. 2004; 28; 1–30.
- 12Chong WH, Molinolo AA, Chen CC et al. Tumor-induced osteomalacia. Endocr. Relat. Cancer 2011; 8; R53–R77.
- 13Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ‘ventrolateral thalamic nucleus of the brain’. Biochem. Biophys. Res. Commun. 2000; 277; 494–498.
- 14Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int. 2004; 65; 1–14.
- 15Bahrami A, Weiss SW, Montgomery E et al. RT–PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am. J. Surg. Pathol. 2009; 33; 1348–1354.
- 16Leaf DE, Pereira RC, Bazari H et al. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J. Clin. Endocrinol. Metab. 2013; 98; 887–891.
- 17Shelekhova KV, Kazakov DV, Hes O et al. Phosphaturic mesenchymal tumor (mixed connective tissue variant): a case report with spectral analysis. Virchows Arch. 2006; 448; 232–235.
- 18Graham R, Krishnamurthy S, Oliveira A et al. Frequent expression of fibroblast growth factor-23 (FGF23) mRNA in aneurysmal bone cysts and chondromyxoid fibromas. J. Clin. Pathol. 2012; 65; 907–909.
- 19Graham RP, Hodge JC, Folpe AL et al. A cytogenetic analysis of 2 cases of phosphaturic mesenchymal tumor of mixed connective tissue type. Hum. Pathol. 2012; 43; 1334–1338.
- 20Mirra JM, Kessler S, Bhuta S et al. The fibroma-like variant of epithelioid sarcoma. A fibrohistiocytic/myoid cell lesion often confused with benign and malignant spindle cell tumors. Cancer 1992; 15; 1382–1395.
- 21Billings SD, Folpe AL, Weiss SW. Epithelioid sarcoma-like hemangioendothelioma. Am. J. Surg. Pathol. 2003; 27; 48–57.
- 22Hornick JL, Fletcher CD. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior. Am. J. Surg. Pathol. 2011; 35; 190–201.
- 23Trombetta D, Magnusson L, von Steyern FV et al. Translocation t(7;19)(q22;q13) – a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma? Cancer Genet. 2011; 204; 211–215.
- 24McGinity M, Bartanusz V, Dengler B et al. Pseudomyogenic hemangioendothelioma (epithelioid sarcoma-like hemangioendothelioma, fibroma-like variant of epithelioid sarcoma) of the thoracic spine. Eur. Spine J. 2013; 22(Suppl. 3); 506–511.
- 25Amary MF, O'Donnell P, Berisha F et al. Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma; characterization of five cases. Skeletal Radiol. 2013; 42; 947–957.
- 26Sheng W, Pan Y, Wang J. Pseudomyogenic hemangioendothelioma: report of an additional case with aggressive clinical course. Am. J. Dermatopathol. 2013; 35; 597–600.
- 27Meis-Kindblom JM, Kindblom L-G. Acral myxoinflammatory fibroblastic sarcoma; a low-grade tumor of the hands and feet. Am. J. Surg. Pathol. 1998; 22; 911–924.
- 28Montgomery EA, Devaney KO, Giordano TJ et al. Inflammatory myxohyaline tumor of distal extremities with virocyte or Reed–Sternberg-like cells: a distinctive lesion with features simulating inflammatory conditions, Hodgkin's disease, and various sarcomas. Mod. Pathol. 1998; 11; 384–391.
- 29Michal M. Inflammatory myxoid tumor of the soft parts with bizarre giant cells. Pathol. Res. Pract. 1998; 194; 529–533.
- 30Sakaki M, Hirokawa M, Wakatsuki S et al. Acral myxoinflammatory fibroblastic sarcoma: a report of five cases and review of the literature. Virchows Arch. 2003; 442; 25–30.
- 31Lambert I, Debiec-Rychter M, Guelinckx P et al. Acral myxoinflammatory fibroblastic sarcoma with unique clonal chromosomal changes. Virchows Arch. 2001; 438; 509–512.
- 32Hallor KH, Sciot R, Staaf J et al. Two genetic pathways, t(1:10) and amplification of 3p11-12, in myxoinflammmatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J. Pathol. 2009; 217; 716–727.
- 33Antonescu CR, Zhang L, Nielsen GP et al. Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosom. Cancer 2011; 50; 757–764.
- 34Fletcher CDM, Bridge JA, Lee JC. Extrapleural solitary fibrous tumour. In CDM Fletcher, JS Bridge, CW Pancras, FM Hogendoorn eds. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press, 2013; 80–82.
- 35Robinson DR, Wu YM, Kalyana-Sundaram S et al. Identification of recurrent NAB2–STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat. Genet. 2013; 45; 180–185.
- 36Chnielecki J, Crago AM, Rosenberg M et al. Whole-exome sequencing identifies a recurrent NAB2–STAT6 fusion in solitary fibrous tumors. Nat. Genet. 2013; 45; 131–132.
- 37Mohajeri A, Tayebwa J, Collin A et al. Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, non-random secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosom. Cancer 2013; 52; 873–886.
- 38Doyle LA, Vivero M, Fletcher CD et al. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod. Pathol. 2013. [Epub ahead of print].
- 39Schweizer L, Koelsche C, Sahm F et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2–STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013; 125; 651–658.
- 40Fletcher CDM, Antonescu CR, Heim S et al. Myoepithelioma. In CDM Fletcher, JS Bridge, CW Pancras, FM Hogendoorn eds. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press, 2013; 208–209.
- 41Antonescu CR, Zhang L, Chang N-E et al. EWSR1–POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosom. Cancer 2010; 49; 1114–1124.
- 42Hornick JL, Fletcher CD. Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters. Am. J. Surg. Pathol. 2003; 27; 1183–1196.
- 43Brandal P, Panagopoulos I, Bjerkehagen B et al. Detection of a t(1;22)(q23;q12) translocation leading to an EWSR1–PBX1 fusion gene in a myoepithelioma. Genes Chromosom. Cancer 2008; 47; 558–564.
- 44Brandal P, Panagopoulos I, Bjerkehagen B et al. t(19;22)(q13;q12) translocation leading to the novel fusion gene EWSR1–ZNF444 in soft tissue myoepithelial carcinoma. Genes Chromosom. Cancer 2009; 48; 1051–1056.
- 45Yamaguchi S, Yamazaki Y, Ishikawa Y et al. EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12). Genes Chromosom. Cancer 2005; 43; 217–222.
- 46Deng FM, Galvan K, de la Roza G et al. Molecular characterization of an EWSR1–POU5F1 fusion associated with a t(6;22) in an undifferentiated soft tissue sarcoma. Cancer Genet. 2011; 204; 423–429.
- 47Möller E, Stenman G, Mandahl N et al. POU5F1, encoding a key regulator of stem cell pluripotency, is fused to EWSR1 in hidradenoma of the skin and mucoepidermoid carcinoma of the salivary glands. J. Pathol. 2008; 215; 78–86.
Citing Literature
